Sign in Subscribe

dmmr

A collection of 116 issues

Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer

Skip to content The CRC Digest ◇ RESEARCH Chemoradiotherapy plus immunotherapy may expand checkpoint blockade benefit in mismatch repair-proficient rectal cancer Adding immune checkpoint blockade to chemoradiotherapy has been associated with pathological complete response rates of 30% or more in pMMR rectal cancer trials, higher than expected with chemoradiotherapy alone, though

Critical review outlines biomarker-guided treatment selection in metastatic CRC

Skip to content The CRC Digest Critical review outlines biomarker-guided treatment selection in metastatic CRC A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol) This content is informational

Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes

Skip to content The CRC Digest Secondary actionable fusions in MLH1-deficient MSI-H tumors may impact pembrolizumab outcomes A molecular subanalysis of the GAstrointestinal INestable cohort evaluated secondary fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab, finding that these fusions may be enriched in MLH1-deficient colorectal cancer with mitogen-activated

Subscribe to The CRC Digest

Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe

The CRC Digest provides research summaries for informational and educational purposes only.
This is not medical advice. Always consult your healthcare provider before making any decisions about your care.

Disclaimer Privacy Policy Terms of Use About